Brief: Senti Bio's SENTI-202, A First-In-Class Off-The-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results In The Treatment Of Patients With Relapsed/Refractory AML

Senti Biosciences Holdings

28/04/2025 12:26

April 28 (Reuters) - Senti Biosciences Inc SNTI.O:

SENTI BIO’S SENTI-202, A FIRST-IN-CLASS OFF-THE-SHELF LOGIC GATED SELECTIVE CD33 OR FLT3 NOT EMCN CAR NK CELL THERAPY, DEMONSTRATES POSITIVE PRELIMINARY CLINICAL RESULTS IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML

Source text: ID:nGNX57fYg6

Further company coverage: SNTI.O

 ((Reuters.Briefs@thomsonreuters.com;))